Skip to content
Parakho

Aurobindo Pharma Ltd

NSE AUROPHARMABSE 524804aurobindo.comInvestor relations

Q1 FY27, unaudited

Revenue
₹9,150.35 Cr
Profit after tax
₹1,032.03 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations9,150.35+16.30%33,653.08
Other income264.23+150.93%492.09
Total income9,414.58+18.07%34,145.17
Employee benefit expense1,480.15+20.45%5,190.17
Finance costs101.66+4.00%383.97
Depreciation & amortisation486.82+20.00%1,778.19
Total expenses7,857.77+16.09%28,969.51
Profit before tax1,516.63+25.87%5,110.33
Tax expense483.06+26.26%1,608.88
Profit after tax1,032.03+25.22%3,502.97
Total comprehensive income985.16−19.91%5,468.17
Earnings per share
Earnings per share, basic₹17.86₹60.34
Earnings per share, diluted₹17.86₹60.34

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Aurobindo Pharma reported Q1 FY27 consolidated revenue up 16% year-on-year to Rs 9,150 crores, with operating EBITDA at Rs 1,924 crores and a margin of 21%, driven by growth across formulations, API, US, Europe and growth markets. Management highlighted the completion of the Lannett acquisition, doubling of production at the China OSD facility, and progress in the biosimilars and TheraNym biologics contract manufacturing pipeline. The company reiterated its FY27 guidance of double-digit revenue growth, EBITDA margins above 21%, and absolute EBITDA exceeding Rs 8,000 crores.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 109 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 09 Oct 2026.